Business
AngioDynamics’ NanoKnife® System Named to TIME’s 2025 Best Inventions List
Function-Preserving Therapy Recognized in the Medical Devices Category for its Use of Irreversible Electroporation (IRE) Technology in Treatment of Prostate
About this update from Angiodynamics, Inc.
[{"type":"text","content":"\nFunction-Preserving Therapy Recognized in the Medical Devices Category for its Use of Irreversible Electroporation (IRE) Technology in Treatment of Prostate Tumors\n\n\n LATHAM, N.Y.--(BUSINESS WIRE)--\nAngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its NanoKnife System has been selected as one of TIME's 2025 Best Inventions. The annual list celebrates groundbreaking products and technologies that are transforming how people live, work, and receive care.\n\n\nFor the past 25 years, TIME’s Best Inventions list has celebrated the most impactful innovations across industries. To create the 2025 edition, its most comprehensive to date, TIME’s editors and correspondents reviewed global nominations and online submissions, placing special focus on rapidly advancing fields such as health care, artificial intelligence, and green energy. Each invention was evaluated on originality, efficacy, ambition, and impact, resulting in a list of 300 breakthroughs shaping the future of technology, medicine, and society.\n\n\nAs TIME noted in its 2025 Best Inventions feature, the NanoKnife System “offers men with intermediate-risk cases of prostate cancer a minimally invasive option before doctors turn to radiation or other traditional cancer treatments that can damage nearby nerves.”\n\n\nProstate cancer is the second most common cancer among men in the United States.1 The NanoKnife System offers a minimally invasive, non-thermal, radiation-free option for prostate tissue ablation using Irreversible Electroporation (IRE) technology, which precisely targets and destroys cancerous cells while preserving surrounding healthy structures.\n\n\nRecognized in the Medical and Healthcare category, the NanoKnife System was selected by TIME for its potential to change the standard of care for the treatment of prostate tumors. The NanoKnife System received U.S. Food and Drug Administration (FDA) 510(k) clearance in late 2024 for prostate tissue ablation. Unlike traditional thermal ablation, the NanoKnife System is designed to preserve surrounding critical structures, helping to maintain both urinary and sexual function.\n\n\n“Recognition by TIME further underscores the importance...